BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, September 14, 2024
See today's BioWorld
Home
» Roche’s Columvi and GSK’s Blenrep among 23 phase III successes in June
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Biopharma clinical updates June 2024
Roche’s Columvi and GSK’s Blenrep among 23 phase III successes in June
July 29, 2024
By
Amanda Lanier
No Comments
In June 2024,
BioWorld
covered 221 clinical trial updates, compared to 298 in May.
BioWorld
recorded 23 phase III trial successes in June, seven failures, and one with mixed results.
BioWorld
Analysis and data insight
Clinical
FDA
